Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Enigma Dx Secures Additional Funding for Multi-Drug Resistant TB Assay

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
This grant will support further development of Enigma's test for multi-drug resistant tuberculosis on its CE Marked Enigma® Mini Laboratory system.

Enigma Diagnostics has already demonstrated feasibility testing of a single tube assay that can identify and differentiate human and bovine TB in an earlier trial, funded by an initial grant from the Technology Strategy Board’s Biomedical Catalyst programme. The multi-drug resistant tuberculosis (MDR-TB) assay also detects all mutations responsible for Rifampicin and Isoniazid resistance. 

The grant of £1.4m was awarded to a consortium led by Enigma Diagnostics which includes the Clinical TB Research Laboratory, London, headed by Prof. F Drobniewski and Health Sciences Research Ltd. Enigma will focus on further development of the MDR-TB assay and fully automated sample preparation for use on Enigma’s flagship Mini Laboratory (ML) system. 

The Enigma® Mini Laboratory system uniquely combines a number of features critical to PoC testing. The fully automated raw sample to result instrument platform delivers results equivalent to central laboratory standards in up to 70 minutes and can be used by non-technical users in both laboratory and decentralised settings. With this assay, the ML system will be particularly appropriate for use in developing countries and in resource-poor areas where multi-drug resistant tuberculosis is an ever-increasing problem. The ML system’s ease of use requires minimal training and has shown nil operator variance in recent trials, a major issue for other laboratory based diagnostic instruments where testing is undertaken by different operators. Together, these features offer physicians a paradigm shift in their ability to make fully informed treatment decisions and patients fast and accurate diagnosis with immediate treatment. 

John McKinley, Chairman of Enigma Diagnostics, said: “With this grant, The Technology Strategy Board has recognised the importance of supporting Enigma to develop complex diagnostic assays on its ML system which can ultimately save patients’ lives. Our sophisticated multiplexing technology provides unprecedented levels of urgently required diagnostic information to clinicians working in a range of healthcare locations. We recognise MDR-TB as a significant healthcare issue and this grant will enable Enigma to broaden its commercialisation programme to include this important test.” 

Integrated into the Technology Strategy Board’s Stratified Medicine Innovation Platform, the Detection & Identification of infectious agents (DIIA) platform was established in 2008 with the aim of reducing the economic burdened, death and illness due to infectious diseases in humans and animals. Projects supported under the DIIA platform have used public funding to encourage the development and adoption of clinically useful, commercially viable diagnostic solutions. 

Dr Penny Wilson, who manages the programme for the Technology Strategy Board, said: “The development of clinically useful decentralised diagnostic tests for tuberculosis requires the convergence of excellence in a broad spectrum of capabilities and we are delighted to be supporting projects in this area for the benefit of economic growth and public health. We wish Enigma Diagnostics every success in rising to the challenge and look forward to following the company’s progress.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Enigma Diagnostics, ICDC Announce MDx Collaboration
Collaboration aims to develop a rapid and convenient MDx technology for infectious disease pathogens utilising Enigma’s proprietary chemistries and the Enigma® Mini Laboratory system.
Thursday, May 15, 2014
Enigma Signs Licence Agreement with the UK Defence Science and Technology Laboratory
The worldwide licence covers a broad range of technologies which are important elements of Enigma’s real-time PCR systems.
Friday, August 24, 2007
Scientific News
Top 10 Life Science Innovations of 2016
2016 has seen the release of some truly innovative products. To help you digest these developments, The Scientist have listed their top picks for the year.
Using Cancer Cells' Mass to Predict Treatment Response
A device has been developed that can detect changes in cell mass at a minute scale.
NVIDIA Awards $400k to Trailblazers in Cancer Research
NVIDIA Foundation furthers research that could lead to new and more targeted treatments with investments.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Working With Advanced Nanoimagers
Oxford Nanoimaging report on the work of early-adopters for their Nanoimager technology at the MRC Centre for Molecular Bacteriology and Infection.
History of Cells Told Through MEMOIR
MEMOIR technique developed by CalTech researchers enables the life history of cells to be read.
Nanoscale ‘Muscles’ Powered by DNA
Scientists have developed nanoscale "muscles" to integrate with custom DNA, that can force the material to bend, curl and flip.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Peer Review is in Crisis, But Should be Fixed, Not Abolished
After the time to get the science done, peer review has become the slowest step in the process of sharing studies, and some scientists have had enough.
Cancer Stem Cells Fuel Tumor Growth
Mass. General, Broad Institute team finds strong evidence that cancer stem cells are important drivers of tumors in patients.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!